News
Advertisement
Advertisement
Advertisement
Advertisement
The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.
The highly specific myostatin activation inhibitor is expected to enter phase 2 study in spinal muscular atrophy, according to SRK-015’s manufacturer, Scholar Rock.
The FDA has set a PDUFA date of March 25, 2020.
The director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about the importance of caring for patients with MS by using a team-based approach.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
2
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
3
Understanding the Global Impact of the Honolulu Asian Aging Study: George W. Ross, MD
4
FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies
5
